FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Naydenov Jordan G
2. Issuer Name and Ticker or Trading Symbol

CytoDyn Inc. [ CYDY ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

1111 MAIN STREET, SUITE 660
3. Date of Earliest Transaction (MM/DD/YYYY)

11/16/2018
(Street)

VANCOUVER, WA 98660
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   11/16/2018     D    5304490   D   (1) (2) 0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (right to buy)   $0.66   11/16/2018     D         50000    6/1/2015   6/1/2019   Common Stock   50000     (1) (2) 0   D    
Stock Options (right to buy)   $2.00   11/16/2018     D         50000    8/8/2012   8/8/2021   Common Stock   50000     (1) (2) 0   D    
Stock Options (right to buy)   $1.55   11/16/2018     D         25000    6/1/2013   6/1/2022   Common Stock   25000     (1) (2) 0   D    
Stock Options (right to buy)   $0.975   11/16/2018     D         50000    9/1/2016   6/1/2025   Common Stock   50000     (1) (2) 0   D    
Stock Options (right to buy)   $1.09   11/16/2018     D         50000    6/1/2017   6/1/2026   Common Stock   50000     (1) (2) 0   D    
Stock Options (right to buy)   $0.57   11/16/2018     D         75000    9/1/2018   6/1/2027   Common Stock   75000     (1) (2) 0   D    
Stock Options (right to buy)   $0.56   11/16/2018     D         96397    2/7/2018   2/7/2028   Common Stock   96397     (1) (2) 0   D    
Stock Options (right to buy)   $0.80   11/16/2018     D         50000    2/15/2018   2/15/2023   Common Stock   50000     (1) (2) 0   D    
Stock Options (right to buy)   $0.49   11/16/2018     D         100000      (3) 6/8/2028   Common Stock   100000     (1) (2) 0   D    
Warrants (right to buy)   $0.75   11/16/2018     D         133334    1/31/2018   1/31/2023   Common Stock   133334     (1) (2) 0   D    
Warrants (right to buy)   $0.75   11/16/2018     D         66666    1/31/2018   7/26/2022   Common Stock   66666     (1) (2) 0   D    
Warrants (right to buy)   $1.35   11/16/2018     D         250000    5/10/2016   5/10/2021   Common Stock   250000     (1) (2) 0   D    

Explanation of Responses:
(1)  On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock.
(2)  In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance).
(3)  The options vest in four equal quarterly installments commencing on September 1, 2018.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Naydenov Jordan G
1111 MAIN STREET, SUITE 660
VANCOUVER, WA 98660
X



Signatures
/s/ Michael D. Mulholland, as attorney-in-fact 11/16/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more CytoDyn (QB) Charts.
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more CytoDyn (QB) Charts.